Study of Osteopontin as a Marker of Arteriovenous Shunt Stenosis in Hemodialysis Patients.

IF 2.8 3区医学 Q2 PERIPHERAL VASCULAR DISEASE Current vascular pharmacology Pub Date : 2024-01-01 DOI:10.2174/0115701611260120231106081701

Marwa R Elbarbary, Laila A Ahmed, Doaa A El-Adl, Alshimaa A Ezzat, Sherif A Nassib

{"title":"Study of Osteopontin as a Marker of Arteriovenous Shunt Stenosis in Hemodialysis Patients.","authors":"Marwa R Elbarbary, Laila A Ahmed, Doaa A El-Adl, Alshimaa A Ezzat, Sherif A Nassib","doi":"10.2174/0115701611260120231106081701","DOIUrl":null,"url":null,"abstract":"Introduction: Although arteriovenous fistula (AVF) is the recommended access for hemodialysis (HD), it carries a high risk for stenosis. Since osteopontin (OPN) is implicated in the process of vascular calcification in HD patients, OPN may be a marker for AVF stenosis. The present study evaluated OPN as a potential marker of AVF stenosis in HD patients.Methods: Diagnosing a stenotic lesion was made by combining B mode with color and pulse wave Doppler imaging. Criteria for diagnosis of stenotic AVF included 50% reduction in diameter in B mode in combination with a 2-3-fold increase of peak systolic velocity compared with the unaffected segment.Results: The present study included 60 HD patients with stenotic AVF and 60 patients with functional AVF. Comparison between the two groups revealed that patients in the former group had significantly higher serum OPN levels [median (IQR): 17.1 (12.1-30.4) vs 5.8 (5.0-10.0) ng/mL, p<0.001]. All patients were classified into those with low (< median) and with high (≥ median) OPN levels. Comparison between these groups revealed that the former group had a significantly lower frequency of stenotic AVF (31.7 vs 68.3%, p<0.001) and a longer time to AVF stenosis [mean (95% CI): 68.4 (54.7-82.1) vs 46.5 (39.6-53.4) months, p=0.001].Conclusion: OPN levels in HD patients may be useful markers for predicting and detecting AVF stenosis.","PeriodicalId":11278,"journal":{"name":"Current vascular pharmacology","volume":" ","pages":"50-57"},"PeriodicalIF":2.8000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current vascular pharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0115701611260120231106081701","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PERIPHERAL VASCULAR DISEASE","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Although arteriovenous fistula (AVF) is the recommended access for hemodialysis (HD), it carries a high risk for stenosis. Since osteopontin (OPN) is implicated in the process of vascular calcification in HD patients, OPN may be a marker for AVF stenosis. The present study evaluated OPN as a potential marker of AVF stenosis in HD patients.

Methods: Diagnosing a stenotic lesion was made by combining B mode with color and pulse wave Doppler imaging. Criteria for diagnosis of stenotic AVF included 50% reduction in diameter in B mode in combination with a 2-3-fold increase of peak systolic velocity compared with the unaffected segment.

Results: The present study included 60 HD patients with stenotic AVF and 60 patients with functional AVF. Comparison between the two groups revealed that patients in the former group had significantly higher serum OPN levels [median (IQR): 17.1 (12.1-30.4) vs 5.8 (5.0-10.0) ng/mL, p<0.001]. All patients were classified into those with low (< median) and with high (≥ median) OPN levels. Comparison between these groups revealed that the former group had a significantly lower frequency of stenotic AVF (31.7 vs 68.3%, p<0.001) and a longer time to AVF stenosis [mean (95% CI): 68.4 (54.7-82.1) vs 46.5 (39.6-53.4) months, p=0.001].

Conclusion: OPN levels in HD patients may be useful markers for predicting and detecting AVF stenosis.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

骨桥蛋白作为血液透析患者动静脉分流管狭窄标志物的研究。

导读:虽然动静脉瘘(AVF)是血液透析(HD)的推荐途径，但它有很高的狭窄风险。由于骨桥蛋白(OPN)与HD患者的血管钙化过程有关，因此OPN可能是AVF狭窄的标志。本研究评估了OPN作为HD患者AVF狭窄的潜在标志。方法:B超结合彩色多普勒和脉搏波多普勒显像对狭窄病变进行诊断。狭窄性AVF的诊断标准包括B型内径缩小50%，同时与未受影响的节段相比，峰值收缩速度增加2-3倍。结果:本研究包括60例HD合并狭窄性AVF和60例功能性AVF。两组比较显示，前者患者血清OPN水平显著高于前者[中位数(IQR): 17.1 (12.1-30.4) vs 5.8 (5.0-10.0) ng/mL]。结论:HD患者的OPN水平可能是预测和检测AVF狭窄的有用指标。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Current vascular pharmacology 医学-外周血管病

CiteScore

9.20

自引率

4.40%

发文量

审稿时长

6-12 weeks

期刊介绍： Current Vascular Pharmacology publishes clinical and research-based reviews/mini-reviews, original research articles, letters, debates, drug clinical trial studies and guest edited issues to update all those concerned with the treatment of vascular disease, bridging the gap between clinical practice and ongoing research. Vascular disease is the commonest cause of death in Westernized countries and its incidence is on the increase in developing countries. It follows that considerable research is directed at establishing effective treatment for acute vascular events. Long-term treatment has also received considerable attention (e.g. for symptomatic relief). Furthermore, effective prevention, whether primary or secondary, is backed by the findings of several landmark trials. Vascular disease is a complex field with primary care physicians and nurse practitioners as well as several specialties involved. The latter include cardiology, vascular and cardio thoracic surgery, general medicine, radiology, clinical pharmacology and neurology (stroke units).